Patent ID: 8236819

Claim:
A method for treating or ameliorating a retinoid X receptor mediated condition in a subject in need thereof, wherein the retinoid X receptor condition is selected from IDDM, NIDDM, IGT, IFG, Syndrome X (or Metabolic Syndrome), insulin resistance, obesity, hyperlipidemia (including, phase I hyperlipidemia, pre-clinical hyperlipidemia, and phase II hyperlipidemia), hypercholesteremia, hypertriglyceridemia, insulin resistance, dyslipidemia, nephropathy, neuropathy, retinopathy, atherosclerosis, low HDL, non-alcoholic steatohepatitis, polycystic ovary syndrome or polycystic ovarian syndrome, hypertension, ischemia, stroke, high blood pressure, heart disease, irritable bowel disorder, inflammation, cardiovascular disorders and cataracts, comprising administering to the subject a therapeutically effective amount of at least one compound of Formula (I) wherein R 1 is H or optionally substituted C 1-3 alkyl; R 2 and R 3 are independently C 1-3 alkyl; R 4 is wherein Z is selected from X is selected from a bond, optionally substituted —O—C 1-5 alkyl-, and optionally substituted C 1-6 alkylene; R a and R b are independently selected from optionally substituted C 1-3 alkyl, optionally substituted —C 2-3 alkenyl, and optionally substituted C 1-3 alkoxy; and m and n are independently selected from 0, 1, and 2, except that m and n cannot both be 2; or alternatively R 4 is H or optionally substituted C 1-3 alkyl; with the proviso that when R 4 is then R 5 cannot be provided further that when R 4 is H or optionally substituted C 1-3 alkyl, then R 5 cannot be H or optionally substituted C 1-3 alkyl; R 5 is wherein Z is selected from X is selected from a bond, optionally substituted —O—C 1-5 alkyl-, and optionally substituted C 1-6 alkylene; R a and R b are independently selected from optionally substituted C 1-3 alkyl, optionally substituted —C 2-3 alkenyl, and optionally substituted C 1-3 alkoxy; and m and n are independently selected from 0, 1, and 2, except that m and n cannot both be 2; or alternatively R 5 is H or optionally substituted C 1-3 alkyl; with the proviso that when R 5 is then R 4 cannot be provided further that when R 5 is H or optionally substituted C 1-3 alkyl, then R 4 cannot be H or optionally substituted C 1-3 alkyl; and R 6 is H or C 1-3 alkyl; or an optical isomer, enantiomer, diastereomer, racemate, or pharmaceutically acceptable salt thereof.